Health economics consultancy for MedTech, diagnostics, and digital health companies entering the UK market. We build the evidence case that shapes your strategy.
Build the health economics case for your technology before you commit to a strategy.
Market intelligence and health economics for your technology transfer portfolio.
Independent market assessment for health technology investment decisions.
Health economics co-applicant for NIHR, SBRI, and Innovate UK bids.
Where does your technology sit in the clinical pathway? What's the addressable market? What evidence does NICE need to see? We build the health economics case that shapes your go-to-market strategy.
We join your grant application as a named co-applicant, contributing the health economics sections, NHS need narrative, and market context. We invest in your application alongside you.
Ongoing market monitoring across your technology portfolio. Market reads on any technology, deeper analysis when you need it, and regular briefings on the landscape your spin-outs compete in.
Independent market assessment for investors evaluating health technology opportunities. Market positioning, regulatory pathway, and commercial viability backed by evidence, not assumptions.
27 years of healthcare expenditure traced. Where the money goes, who pays, and what the trends tell us.
27 February 2026New Alzheimer’s drugs rejected by NICE. Blood biomarker trials underway. A decade of evidence on the growing infrastructure gap.
8 March 2026Billions in public R&D investment stalls for want of £250k in proof-of-concept funding. The bottleneck is smaller than you think.
28 February 2026We work with tech transfer offices, MedTech companies, and investors. Our clients range from university spin-outs preparing for market entry to established companies building their UK health technology strategy.
Early economic modelling, value proposition development, NICE strategy, clinical pathway analysis, evidence gap assessment, and reimbursement business cases
Direct experience interviewing clinicians, commissioners, and procurement leads across NHS trusts and ICBs
Active relationships with university technology transfer offices and health innovation networks across the North of England
We maintain a depth of understanding across the UK health technology landscape that means we're never starting from scratch
We help MedTech companies build the evidence case for NHS adoption. That means market sizing, budget impact modelling, cost-effectiveness analysis, NICE submission strategy, and reimbursement business cases. For diagnostics, AI, digital health and medical devices entering the UK market, health economics evidence is essential for NICE evaluation, commissioner engagement, and investor confidence.
NICE evaluates medical devices and diagnostics through several routes including the Diagnostics Assessment Programme, Medical Technologies Evaluation Programme, and Health Technology Evaluation. Each requires clinical evidence and economic analysis. We advise on which route is appropriate, identify evidence gaps, and build the economic models and submission documents.
Market access strategy involves understanding NHS commissioning structures, building the economic case for adoption, navigating NICE and HTA requirements, and engaging with Integrated Care Boards and NHS trusts. It covers market sizing, competitive landscape analysis, pricing and reimbursement, and the evidence package NHS decision-makers need to adopt a new technology.
Total UK healthcare expenditure reached £317 billion in 2024. Medical goods including diagnostics, devices and pharmaceuticals account for approximately £34 billion. Spending is distributed across 42 Integrated Care Boards and hundreds of NHS trusts, with significant regional variation in adoption and expenditure. Read our full spending analysis →
Yes. We join grant applications as a named co-applicant, contributing the health economics sections, NHS needs narrative, and market context. We work across NIHR i4i, SBRI Healthcare, Innovate UK Biomedical Catalyst, and similar funding programmes for health technology innovation.
We work across diagnostics (in-vitro and point-of-care), medical devices, AI and software as a medical device (SaMD), digital health platforms, biosensors, and clinical decision support tools. Our expertise spans the full range of health technology entering the UK NHS market.
Whether you need a market landscape, a NICE strategy, or the health economics case for a grant.